- eric piermont/Agence France-Presse/Getty ImagesNeurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, giving it the first approved treatment for a rare genetic disorder that causes relentless, life-threatening hunger. Most Read from The Wall Street JournalSoleno’s treatment, called Vykat XR, won Food and Drug Administration approval in March 2025 as the first and only treatment for the condition. Neurocrine agreed to pay $53 a share in cash, a roughly 34% premium to Soleno’s closing share price on April 2. Vykat XR’s patents are expected to keep competitors from selling a rival version until the mid-2040s, according to Neurocrine. Write to Nicholas G. Miller at nicholas.miller@wsj.com and Xavier Martinez at xavier.martinez@wsj.comMost Read from The Wall Street Journal

Source: Wall Street Journal April 06, 2026 12:57 UTC